Age-dependent changes in nitric oxide synthase activity and protein expression in striata of mice transgenic for the Huntington's disease mutation

Brain Research

Volumn 951, Issue 1, 2002, Pages 36-42

  Pérez Severiano, Francisca ^a,b   Escalante, Bruno ^a   Vergara, Paula ^a   Ríos, Camilo ^b   Segovia, José ^a  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

^b NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

Author keywords

Basal ganglia; Huntington's disease; Motor behavior; Nitric oxide; Oxidative damage; Striatum; Transgenic mouse

Indexed keywords

NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; DISEASE COURSE; ENZYME ACTIVITY; EXON; FEMALE; HUNTINGTON CHOREA; MALE; MOUSE; NONHUMAN; OXIDATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; TRANSGENIC MOUSE; WILD TYPE;

AGING; ANIMALS; BODY WEIGHT; CALCIUM; CALCIUM SIGNALING; FEMALE; HUNTINGTON DISEASE; LIPID PEROXIDATION; MALE; MICE; MICE, TRANSGENIC; NEOSTRIATUM; NEURONS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXIDATIVE STRESS; PHENOTYPE;

EID: 0037183717     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(02)03102-5     Document Type: Article

References (42)

1. Beal M.F. Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci. 23:2000;298-304.
2. Bogdanov M.B., Andreassen O.A., Dedeoglu A., Ferrante R.J., Beal M.F. Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease. J. Neurochem. 79:2001;1246-1249.
3. Bredt D.S., Snyder S.H. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc. Natl. Acad. Sci. USA. 87:1990;682-685.
4. Bredt D.S., Hwang P.M., Glatt C.E., Lowenstein C., Reed R.R., Snyder S.H. Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase. Nature. 351:1991;714-718.
5. Browne S.E., Bowling A.C., MacGarvey U., Baik M.J., Berger S.C., Muqit M.M., Bird E.D., Beal M.F. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann. Neurol. 41:1997;646-653.
6. Busse R., Mulsch A. Calcium-dependent nitric oxide synthesis in endothelial cytosol is mediated by calmodulin. FEBS Lett. 265:1990;133-136.
7. Calabrese V., Bates T.E., Stella A.M. NO synthase and NO-dependent signal pathways in brain aging and neurodegenerative disorders: the role of oxidant/antioxidant balance. Neurochem. Res. 25:2000;1315-1341.
8. Chabrier P.E., Demerlé-Pallardy C., Auguet M. Nitric oxide synthases: targets for therapeutics strategies in neurological diseases. Cell Mol. Life Sci. 55:1999;1029-1035.
9. Chen M., Ona V.O., Li M., Ferrante R.J., Fink K.B., Zhu S., Bian J., Guo L., Farrell L.A., Hersch S.M., Hobbs W., Vonsattel J.-P., Cha J.-H.J., Friedlander R.M. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of huntington disease. Nat. Med. 6:2000;797-801.
10. Davey G.P., Peuchen S., Clark J.B. Energy thresholds in brain mitochondria. Potential involvement in neurodegeneration. J. Biol. Chem. 273:1998;12753-12757.
11. Dawson V.L., Dawson T.M., London E.D., S Bredt D., Snyder S.H. Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc. Natl. Acad. Sci. USA. 88:1991;6368-6371.
12. Deckel A.W., Gordinier A., Nuttal D., Tang V., Kuwada C., Freitas R., Gary K.A. Reduced activity and protein expression of NOS in R6/2 HD transgenic mice: effects of L-NAME on symptom progression. Brain Res. 919:2001;70-81.
13. A.W. Deckel, D. Nuttal, V. Tang, C. Kuwanda, K. Gary, R. Freitas, Decreased NOS Triggers Pathophysiological Changes in Huntington's Disease Transgenic Mice: Crossbreeding of HD X nNOS -/-. Abstract Society for Neuroscience 31st (2001) Program number 432.7.
14. Díaz-Barriga F., Hernández J.M., Carrizales L., Domínguez M.C., Yañez L., Palmer E., Saborio J.L. Interactions of cadmium with actin microfilaments. Toxicol. Vitro. 3:1989;277-284.
15. Espey M.G., Miranda K.M., Feelisch M., Fukuto J., Grisham M.B., Vitek M.P., Wink D.A. Mechanisms of cell death governed by the balance between nitrosative and oxidative stress. Ann. NY Acad. Sci. 899:2000;209-221.
16. Galpern W.R., Matthews R.T., Beal M.F., Isacson O. NGF attenuates 3-nitrotyrosine formation in a 3-NP model of Huntington's disease. Neuroreport. 7:1996;2639-2642.
17. Garthwaite J., Charles S.L., Chess-Williams R. Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain. Nature. 336:1988;385-388.
18. Harper P.S. Huntington's Disease. 1996;Saunders, London.
19. N. Hogg, Pro-oxidant and antioxidant effects of nitric oxide, in: A.E. Favier et al. (Eds.), Analysis of Free Radicals in Biological Systems. Birkhauser, Basle, 1995, pp. 37-49.
20. 1H NMR spectroscopy. Neurology. 43:1993;2689-2695.
21. 847 phosphorylation in NG108-15 neuronal cells. J. Biol. Chem. 275:2000;28139-28143.
22. Lipton S.A., Choi Y.B., Pan Z.H., Lei S.Z., Chen H.S., Sucher N.J., Loscalzo J., Singel D.J., Stamler J.S. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature. 364:1993;626-632.
23. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., P Bates G. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 87:1996;493-506.
24. Manzoni O., Prezeau L., Marin P., Deshager S., Bockaert J., Fagni L. Nitric oxide-induced blockade of NMDA receptors. Neuron. 8:1992;653-662.
25. McMurray C.T. Huntington's disease: new hope for therapeutics. Trends Neurosci. 24:2001;S32-S38.
26. Moncada S., Palmer R.M.P., Higgs E.A. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol. Rev. 43:1991;109-143.
27. Nishino H., Hida H., Kumazaki M., Shimano Y., Nakajima K., Shimizu H., Ooiwa T., Baba H. The striatum is the most vulnerable region in the brain to mitochondrial energy compromise: a hypothesis to explain its specific vulnerability. J. Neurotrauma. 17:2000;251-260.
28. Norris P.J., Waldvogel H.J., Faull R.L., Love D.R., Emson P.C. Decreased neuronal nitric oxide synthase messenger RNA and somatostatin messenger RNA in the striatum of Huntington's disease. Neuroscience. 72:1996;1037-1047.
29. Pérez-Severiano F., Escalante B., Ríos C. Nitric oxide synthase inhibition prevents acute quinolinate-induced striatal neurotoxicity. Neurochem. Res. 23:1998;1297-1302.
30. Pérez-Severiano F., Ríos C., Segovia J. Striatal oxidative damage parallels the expression of a neurological phenotype in mice transgenic for the mutation of Huntington's disease. Brain Res. 862:2000;234-237.
31. F. Pérez, C. Ríos, B. Escalante, J. Segovia-Vila, Age-dependent Changes in Nitric Oxide Synthase Activity in Striatum of Mice Transgenic for the Huntington's Disease Mutation. Society for Neuroscience 31st (2001) Program number 432.4.
32. Petersén Å., Mani K., Brundin P. Recent advances on the pathogenesis of Huntington's disease. Exp. Neurol. 157:1999;1-18.
33. Petersén Å., Hansson O., Puschban Z., Sapp E., Romero N., Castilho R.F., Sulzer D., Rice M., DiFiglia M., Przedborski S., Brundin P. Mice transgenic for exon 1 of the Huntington's disease gene display reduced striatal sensitivity to neurotoxicity induced by dopamine and 6-hydroxydopamine. Eur. J. Neurosci. 14:2001;1425-1435.
34. Rubbo H., Radi R., Trujillo M., Telleri R., Kalyanaraman B., Barnes S., Kirk M., Freeman B.A. Nitric oxide regulation of superoxide and peroxynitrite-dependent lipid peroxidation. J. Biol. Chem. 269:1994;26066-26091.
35. Santamaría A., Perez-Severiano F., Rodríguez-Martínez E., Maldonado P.D., Pedraza-Chaverri J., Ríos C., Segovia J. Comparative analysis of superoxide dismutase activity between acute pharmacological models and a transgenic mouse model of Huntington's disease. Neurochem. Res. 26:2001;419-424.
36. Schapira A.H.V. Mitochondrial disorders. Curr. Opin. Neurol. 13:2000;527-532.
37. Schuman E.M., Madison D.V. Nitric oxide and synaptic function. Annu. Rev. Neurosci. 17:1994;153-183.
38. Segovia J., Vergara P., Brenner M. Differentiation-dependent expression of transgenes in engineered astrocyte cell lines. Neurosci. Lett. 242:1998;172-176.
39. Segovia J. Transgenic model for the study of oxidative damage in Huntington's disease. Methods Enzymol. 353:2002;365-373.
40. Tabrizi S.J., Workman J., Hart P.E., Mangiarini L., Mahal A., Bates G., Cooper J.M., Schapira A.H.V. Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Ann. Neurol. 47:2000;80-86.
41. The Huntington's Disease Collaborative Group . A novel gene containing trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 72:1993;971-983.
42. Wink D.A., Vodovotz Y., Grisham M.V., Degraff W., Cook J.C., Pacelli R., Krishna M., Mitchell J.B. Antioxidant effects of nitric oxide. Methods Enzymol. 301:1999;413-424.